Table 2.
Treatment characteristics.
| Variables | COVID-n = 117 (%) | Pre-COVID-n = 190 (%) | P-value |
|---|---|---|---|
| Days symptoms to provider (Median-IQR) | 78.5 (30-120) | 52.5 (12-90) | 0.12 |
| Days provider to EGD (Median-IQR) | 45 (28.8-75.3) | 18 (8-45) | 0.004 |
| Days EGD to treatment (Median-IQR) | 38.5 (30.5-48) | 36 (23-47.5) | 0.48 |
| Initial treatment offered | 0.88 | ||
| Chemo-Radiation | 67 (73.6) | 89 (70.6) | |
| Chemotherapy only | 20 (22.0) | 32 (25.4) | |
| Radiation only | 4 (4.4) | 5 (4.0) | |
| Type of surgical intervention | |||
| Ivor-Lewis esophagectomy | 35 | 45 | |
| Trans-hiatal esophagectomy | 5 | 7 | |
| 3-incision esophagectomy | 4 | 4 | |
| EMR/RFA | 2 | 6 | |
| Endoscopic stenting | 0 | 4 | |
| PEG/J-tube | 6 | 12 | |
| Esophagectomies at our institute | 41/117 (35%) | 49/190 (25.8%) | 0.10 |
| Length of ICU stay-days (median-IQR) | 2 (1-4) | 3 (1-6) | 0.16 |
| Length of hospital stay-days (median-IQR) | 14 (11-17) | 15 (11-22) | 0.28 |
| 30-day post-operative morbidity | 0.48 | ||
| Any Morbidity | 26 (63.4%) | 31 (63.2%) | |
| None | 15 | 18 | |
| Afib/Vtach/BBB | 11 | 12 | |
| PNA | 7 | 9 | |
| Reintubation | 3 | 7 | |
| PE/DVT | 4 | 4 | |
| C.Diff | 1 | 2 | |
| SSI | 6 | 5 | |
| Splenic Infarct | 0 | 1 | |
| GI Bleed | 0 | 1 | |
| UTI | 0 | 4 | |
| Vocal cord dysfunction | 1 | 1 | |
| Anastomotic Leak | 1 | 5 | |
| Chyle Leak | 6 | 5 | |
| Reoperation | 1 | 3 | |
| 30-day readmission | 4 (9.8%) | 4 (8.2%) | 0.79 |
| 30-day mortality | 0 | 1 | |
| 90-day mortality | 0 | 2 | |
| 1-year overall survival (95% CI) | 83.7% (73.8-90.1) | 76.4% (66.9-83.5) | 0.58 |